BioCentury
ARTICLE | Company News

Tetragenetics in pair of protein expression deals

April 2, 2013 12:09 AM UTC

Tetragenetics Inc. (Cambridge, Mass.) announced a pair of deals with Amgen Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE) to produce proteins for antibody screens that would be difficult to make in standard expression systems. Under its deal with Amgen, Tetragenetics is using its TetraExpress Tetrahymena thermophila-based technology to express an undisclosed surface antigen selected by Amgen. The partners will jointly develop antibodies against the target. Amgen was off $0.20 to $102.31 on Monday.

Separately, Tetragenetics partnered to use its SionX platform with Pfizer to express an undisclosed ion channel selected by the pharma for antibody development. Pfizer has an exclusive option to license the resulting preparations, but the partners have not determined who will be responsible for developing compounds based on the preparations. ...